What is OpenEvidence?
AI medical search and clinical decision-support platform for verified clinicians.
- Category
- Medical AI search
- Headquarters
- Miami, Florida
- Founded
- 2022
- Employees
- Private; rapidly scaling team reported
- Total funding
- About $700 million reported
- Valuation
- $12 billion reported in January 2026
What is OpenEvidence?
OpenEvidence is a medical ai search company headquartered in Miami, Florida.
OpenEvidence provides a medical AI search engine grounded in peer-reviewed literature and clinical references for verified physicians. The company reported hundreds of thousands of registered U.S. physicians and millions of clinical consultations per month in 2025-2026 coverage.
The company was founded in 2022 and remains private. Its public profile is strongest around Medical AI search and DeepConsult, while detailed revenue figures are not publicly disclosed.
As of June 2026, the safest public read is that OpenEvidence is scaling through enterprise partnerships and capital-intensive product development rather than a self-serve consumer motion.
What does OpenEvidence offer?
OpenEvidence's public product set centers on Medical AI search, DeepConsult, Publisher partnerships.
- Medical AI search· Clinical decision support
- DeepConsult· Reasoning/search
- Publisher partnerships· Medical content
- Physician verification· Access control
Sources:OpenEvidence website
How does OpenEvidence make money?
Free access for verified clinicians with revenue reported from advertising and sponsored medical education partnerships.
Free access for verified clinicians with revenue reported from advertising and sponsored medical education partnerships. Clinician access is publicly described as free for verified physicians; commercial pricing for sponsors is not public.
Growth is driven by enterprise adoption, strategic partnerships, and proof that the platform can deliver measurable operational, clinical, scientific, or mission outcomes. Because OpenEvidence does not publish standard list prices, buyers should treat budget sizing as a custom-contract exercise.
The commercial motion therefore depends on executive sponsorship, security and compliance review, and evidence that the product can integrate into existing workflows rather than replace them all at once.
Who leads OpenEvidence?
OpenEvidence is led by Daniel Nadler, Co-founder and CEO.
- Daniel NadlerCo-founder and CEOCo-founder · since 2022Former Kensho founder leading strategy.
- Zachary ZieglerCo-founderCo-founder · since 2022Machine-learning researcher and co-founder.
- Mayo Clinic collaboratorsClinical partnersPartner networkClinical validation and distribution relationships.
How do you contact OpenEvidence's leadership?
Public website/contact route; no verified personal email pattern found. Use the listed public company route rather than guessed personal inboxes.
Public website/contact route; no verified personal email pattern foundSources:OpenEvidence website
How much funding has OpenEvidence raised?
OpenEvidence has about $700 million reported and is private.
2025-02: Series A — $75 million, led/backed by Sequoia Capital ($1 billion valuation). 2025-07: Series B — $210 million, led/backed by GV and Kleiner Perkins ($3.5 billion valuation). 2025-10: Series C — $200 million, led/backed by Reported growth investors ($6 billion valuation). 2026-01: Series D — $250 million, led/backed by Reported investors including GV, Nvidia, Blackstone and others ($12 billion valuation).
The latest public valuation/status marker is $12 billion reported in January 2026. Where a valuation is undisclosed, public reporting only supports the financing amount and participating investors.
Funding is best interpreted as capacity for product build-out, hiring, regulatory or deployment work, and longer sales cycles; it should not be read as proof of profitability unless the company has separately disclosed profitability.
How did OpenEvidence get here?
OpenEvidence's timeline runs from its 2022 founding through major financing and product milestones.
- 2022FoundedOpenEvidence launched to make medical literature searchable for clinicians.
- 2023Mayo Clinic acceleratorThe company participated in health-technology acceleration and validation.
- 2025Series A unicorn roundSequoia led funding at a $1 billion valuation.
- 2025Major publisher partnershipsOpenEvidence announced content relationships with medical societies and journals.
- 2026$12 billion valuationA January 2026 financing reportedly doubled the company's valuation.
Who are OpenEvidence's competitors?
OpenEvidence competes with specialized startups and larger platform companies in medical ai search.
OpenEvidence — frequently asked questions
